Hi suzuki, whatever happens the current IP is definitely not ‘rubbish’ nor likely to disappear and never be ‘seen again’, most especially if apps to become ‘first in its field’.
TAVR still in R&D and a ways to go, ton of comp out there, not sure if this is viable (fanciful thinking) but could a existing TAVR player use this IP to ‘perfect’ or compliment or refine their own?
Current Adapt platform tech earning 10 mill plus, with its expanding and refining portfolio you could reasonably expect this to compound significantly, especially so if in the hands of a major player.
Thats the ‘pot of gold’ Admedus has, .... what absolutely matters to RIs is getting a share of that, SIO will undeniably (and the other cornerstone investor) get the ‘captains’ share, the ‘crew’ (RIs) their much smaller and corresponding share.
How much that portion will be is utterly dependent on the skill of WP to negotiate said deal/s.
Footnote to previous post; the comment that ‘our product is as good as the Admedus one’, they are going to admit it’s better are they? Lol.
- Forums
- ASX - By Stock
- AVR
- Under the Radar
Under the Radar, page-492
-
- There are more pages in this discussion • 47 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$9.91 |
Change
-0.090(0.90%) |
Mkt cap ! $209.4M |
Open | High | Low | Value | Volume |
$10.00 | $10.00 | $9.65 | $70.76K | 7.202K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 300 | $9.80 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$9.91 | 475 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 300 | 9.800 |
1 | 200 | 9.600 |
1 | 2 | 9.540 |
1 | 330 | 9.510 |
2 | 1185 | 9.500 |
Price($) | Vol. | No. |
---|---|---|
9.910 | 475 | 2 |
9.990 | 99 | 1 |
10.000 | 250 | 1 |
10.500 | 10005 | 2 |
11.000 | 5000 | 1 |
Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online